Menarini - Von Heyden GmbH, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in contract manufacturing and development services. Founded in 2010, the company has established a strong presence across Europe, focusing on high-quality production of solid dosage forms, including tablets and capsules. With a commitment to innovation and quality, Menarini - Von Heyden GmbH offers unique solutions tailored to meet the specific needs of its clients. The company is renowned for its state-of-the-art facilities and adherence to stringent regulatory standards, ensuring the delivery of safe and effective products. As a subsidiary of the Menarini Group, it has achieved significant milestones, positioning itself as a trusted partner in the pharmaceutical sector. Its dedication to excellence and customer satisfaction has solidified its reputation in the competitive landscape of contract manufacturing.
How does Menarini - Von Heyden GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Menarini - Von Heyden GmbH's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Menarini - Von Heyden GmbH, headquartered in Germany, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing carbon emissions at this time. As a current subsidiary of Menarini - Von Heyden GmbH, any potential climate initiatives or emissions data may be influenced by the broader corporate strategies of its parent organisation. However, no specific initiatives or targets have been cascaded from the parent company that would provide insight into their climate commitments. In the context of the pharmaceutical industry, where Menarini operates, there is an increasing emphasis on sustainability and carbon reduction. Companies are often encouraged to adopt Science-Based Targets (SBTi) and participate in initiatives like the Carbon Disclosure Project (CDP) to enhance transparency and accountability regarding their environmental impact. Overall, while Menarini - Von Heyden GmbH currently lacks specific emissions data and reduction commitments, the industry context highlights the importance of developing robust climate strategies moving forward.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Menarini - Von Heyden GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.